Publication & Citation Trends
Publications
0 total
The Discovery of RP-2119: A Potent, Selective, and Orally Bioavailable Polθ ATPase Inhibitor.
Cited by 7
Semantic Scholar
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500).
Cited by 21
Semantic Scholar
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition OA
Cited by 0
Semantic Scholar
Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ. OA
Cited by 52
Semantic Scholar
Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306. OA
Cited by 54
Semantic Scholar
Abstract 5650: RP-6306, a novel PKMYT1 inhibitor, demonstrates synthetic lethality as monotherapy and in combination with gemcitabine in CCNE1 amplified cancer cells
Cited by 1
Semantic Scholar
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors OA
Cited by 56
Semantic Scholar
Research Topics
DNA Repair Mechanisms
(9)
PARP inhibition in cancer therapy
(9)
PI3K/AKT/mTOR signaling in cancer
(6)
Immune Cell Function and Interaction
(6)
Cytokine Signaling Pathways and Interactions
(6)
Affiliations
TransCanada (Canada)
Jewish General Hospital
Medicines Discovery Catapult
Terry Fox Research Institute
Merck Canada Inc. (Canada)